VIVE - Viveve Medical Inc Stock Price, Fair Value and News

0USD0Market Closed

VIVE Stock Price

View Fullscreen

VIVE RSI Chart

VIVE Valuation

EV/EBITDA

0.29

VIVE Price/Sales (Trailing)

VIVE Profitability

VIVE Fundamentals

VIVE Revenue

VIVE Earnings

Breaking Down VIVE Revenue

Trailing 12 Months

-100%

How does VIVE drawdown profile look like?

VIVE Financial Health

VIVE Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	6.6M	6.8M	6.8M	0
2021	5.6M	6.6M	6.7M	6.4M
2020	4.9M	4.5M	5.0M	5.5M
2019	17.8M	13.4M	9.6M	6.6M
2018	15.9M	18.4M	19.1M	18.5M
2017	8.9M	10.4M	12.6M	15.3M
2016	2.7M	4.2M	5.4M	7.1M
2015	154.0K	154.0K	721.0K	1.4M
2014	148.4K	144.9K	141.3K	163.0K
2013	225.1K	200.7K	176.4K	152.0K
2012	565.6K	460.2K	354.8K	249.4K
2011	608.0K	629.0K	650.0K	671.0K
2010	0	0	0	587.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Viveve Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 15, 2021	durbin scott	back to issuer	-2.8	1.4	-2.00	chief executive officer
Dec 15, 2021	basta steven l	back to issuer	-39.48	1.41	-28.00	-
Dec 15, 2021	robbins jim b	back to issuer	-51.48	1.43	-36.00	svp, finance & administration
Oct 01, 2019	goldman sachs group inc	sold	-131,711	5.56022	-23,688	-
Sep 30, 2019	goldman sachs group inc	sold	-312,753	4.55	-68,737	-
Sep 27, 2019	goldman sachs group inc	sold	-27,330	5.1	-5,359	-
Sep 26, 2019	goldman sachs group inc	sold	-36,755	5.25	-7,001	-
Sep 25, 2019	goldman sachs group inc	sold	-60,690	5.62	-10,799	-
Sep 24, 2019	goldman sachs group inc	bought	147,768	5.64	26,200	-
Sep 24, 2019	goldman sachs group inc	sold	-4,456	5.57	-800	-

Which funds bought or sold VIVE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 14, 2024	OLD POINT TRUST & FINANCIAL SERVICES N A	new	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%

Are Funds Buying or Selling VIVE?

Are funds buying VIVE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VIVE

No. of Funds

Unveiling Viveve Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 04, 2022	hudson bay capital management lp	2.38%	258,064	SC 13G/A
Jan 18, 2022	empery asset management, lp	4.99%	1,029,411	SC 13G/A
Feb 16, 2021	alyeska investment group, l.p.	2%	163,000	SC 13G/A
Feb 11, 2021	hudson bay capital management lp	9.99%	240,989	SC 13G/A
Jan 19, 2021	empery asset management, lp	9.96%	675,000	SC 13G
Jan 19, 2021	lincoln park capital fund, llc	9.99%	701,000	SC 13G
Feb 14, 2020	alyeska investment group, l.p.	6.1%	244,811	SC 13G
Feb 14, 2020	rtw investments, lp	0%	0	SC 13G/A
Feb 13, 2020	cr group l.p.	67.2%	6,986,473	SC 13G
Feb 13, 2020	hood river capital management llc	0%	0	SC 13G/A

Viveve Medical Inc News

Latest updates

Viveve Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Revenue	-6.2%	1,684,000	1,795,000	1,641,000	1,706,000	1,616,000	1,654,000	1,450,000	1,947,000	1,524,000	704,000	1,304,000	1,451,000	1,052,000	1,052,000	3,012,000	4,472,000	4,821,000	5,525,000	3,699,000	5,101,000	4,070,000
Gross Profit	85.7%	546,000	294,000	320,000	-41,000	114,000	165,000	382,000	247,000	241,000	-367,000	175,000	-119,000	-47,000	111,000	1,071,000	1,665,000	1,494,000	2,814,000	1,347,000	2,772,000	2,011,000
Operating Expenses	-2.0%	5,208,000	5,314,000	5,793,000	5,946,000	5,606,000	5,110,000	5,511,000	4,570,000	3,645,000	4,574,000	6,002,000	6,934,000	6,481,000	8,432,000	9,848,000	13,933,000	12,556,000	13,109,000	12,687,000	12,201,000	10,833,000
S&GA Expenses	0.4%	3,408,000	3,393,000	3,653,000	3,085,500	2,911,000	2,930,000	3,581,000	3,190,000	2,761,000	3,350,000	4,365,000	5,175,000	5,032,000	5,530,000	6,626,000	11,187,000	9,114,000	9,437,000	8,931,000	9,150,000	7,369,000
R&D Expenses	-6.3%	1,800,000	1,921,000	2,140,000	2,860,500	2,695,000	2,180,000	1,930,000	1,380,000	884,000	1,224,000	1,637,000	1,759,000	1,449,000	2,902,000	2,480,000	2,746,000	3,442,000	3,672,000	3,756,000	3,051,000	3,464,000
EBITDA Margin	4.8%	-2.99	-3.14	-2.99	-3.06	-2.70	-2.41	-3.36	-3.53	-5.75	-7.05	-6.89	-5.54	-	-	-	-	-	-	-	-	-
Interest Expenses	2.8%	292,000	284,000	270,000	266,000	255,000	245,000	234,000	242,000	235,000	223,000	210,000	835,000	1,209,000	1,194,000	1,116,000	1,133,000	1,106,000	1,063,000	1,070,000	784,000	777,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	6.9%	-4,976,000	-5,344,000	-5,764,000	-6,260,000	-5,825,000	-3,971,000	-5,715,000	-4,695,000	-3,680,000	-7,029,000	-6,128,000	-14,621,000	-7,788,000	-9,586,000	-9,904,000	-13,374,000	-12,172,000	-11,358,000	-12,420,000	-10,224,000	-9,615,000
EBT Margin	4.6%	-3.27	-3.43	-3.30	-3.39	-3.03	-2.75	-3.75	-3.93	-6.31	-7.88	-7.85	-6.38	-	-	-	-	-	-	-	-	-
Net Income	14.2%	-4,976,000	-5,799,000	-5,886,000	-6,328,000	-5,858,000	-4,050,000	-5,791,000	-4,755,000	-3,735,000	-7,115,000	-6,310,000	-14,817,000	-7,956,000	-9,724,000	-10,029,000	-13,492,000	-12,304,000	-11,516,000	-12,669,000	-10,224,000	-9,615,000
Net Income Margin	4.7%	-3.37	-3.53	-3.34	-3.43	-3.07	-2.79	-3.80	-4.00	-6.42	-8.02	-7.99	-6.48	-	-	-	-	-	-	-	-	-
Free Cashflow	23.4%	-3,543,000	-4,627,000	-5,136,000	-3,521,000	-2,747,000	-3,728,000	-3,338,000	-2,676,000	-2,858,000	-4,584,000	-5,897,000	-5,613,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Assets	-21.5%	12.00	15.00	21.00	26.00	30.00	34.00	38.00	17.00	20.00	21.00	21.00	27.00	24.00	25.00	35.00	47.00	36.00	49.00	57.00	36.00	33.00
Current Assets	-27.5%	10.00	13.00	17.00	22.00	27.00	31.00	34.00	12.00	16.00	16.00	17.00	22.00	19.00	21.00	30.00	42.00	32.00	45.00	53.00	32.00	29.00
Cash Equivalents	-37.4%	6.00	9.00	14.00	19.00	23.00	25.00	28.00	7.00	9.00	9.00	9.00	13.00	9.00	10.00	18.00	30.00	20.00	30.00	38.00	21.00	19.00
Inventory	1.0%	2.00	2.00	2.00	1.00	2.00	3.00	3.00	3.00	5.00	5.00	4.00	5.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00	2.00	2.00
Net PPE	-9.4%	1.00	1.00	1.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00
Liabilities	7.4%	11.00	10.00	11.00	11.00	10.00	9.00	10.00	10.00	9.00	10.00	9.00	10.00	39.00	39.00	39.00	42.00	39.00	40.00	38.00	39.00	26.00
Current Liabilities	8.2%	11.00	10.00	10.00	5.00	4.00	3.00	4.00	4.00	3.00	5.00	5.00	6.00	6.00	7.00	7.00	11.00	9.00	10.00	8.00	9.00	8.00
Shareholder's Equity	-77.6%	1.00	5.00	10.00	15.00	20.00	25.00	28.00	7.00	11.00	11.00	13.00	17.00	-	-	-	5.00	-	9.00	19.00	-	7.00
Retained Earnings	-2.0%	-258	-253	-247	-241	-235	-229	-225	-219	-215	-211	-204	-197	-183	-175	-165	-155	-141	-129	-118	-105	-95.36
Additional Paid-In Capital	0.3%	260	259	258	257	256	255	253	227	226	222	217	214	168	161	161	160	139	138	137	103	102
Shares Outstanding	0.3%	11.00	11.00	11.00	11.00	11.00	10.00	9.00	2.00	2.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	31.00	-	-	-	9.00	-	-	-	18.00	-	-	-	68.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Cashflow From Operations	26.7%	-3,350	-4,568	-5,087	-3,227	-2,663	-3,735	-3,253	-2,298	-2,747	-4,453	-5,736	-5,374	-6,608	-7,696	-11,558	-9,845	-10,011	-8,043	-15,191	-8,579	-8,943
Share Based Compensation	-4.5%	868	909	960	1,014	1,088	867	810	642	642	657	710	766	518	621	496	742	765	775	753	558	487
Cashflow From Investing	-227.1%	-193	-59.00	-49.00	-294	-84.00	7.00	-85.00	-378	-111	-131	-161	-239	-130	-539	-179	-1,159	-180	-341	-462	-95.00	-2,910
Cashflow From Financing	46.2%	19.00	13.00	19.00	18.00	21.00	673	25,261	-1.00	3,600	4,042	1,631	9,835	6,318	-80.00	35.00	20,430	75.00	219	33,301	10,197	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VIVE Income Statement

2022-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue	$ 1,684	$ 1,616	$ 5,120	$ 4,720
Cost of revenue	1,138	1,502	3,960	4,059
Gross profit	546	114	1,160	661
Operating expenses:
Research and development	1,800	2,695	5,861	6,804
Selling, general and administrative	3,408	2,911	10,454	9,423
Total operating expenses	5,208	5,606	16,315	16,227
Loss from operations	(4,662)	(5,492)	(15,155)	(15,566)
Gain on forgiveness of Paycheck Protection Program loan	0	0	0	1,358
Modification of warrants	0	0	0	(373)
Interest expense, net	(292)	(255)	(846)	(734)
Other expense, net	(22)	(78)	(83)	(196)
Net loss from consolidated companies	(4,976)	(5,825)	(16,084)	(15,511)
Impairment loss on investment in unconsolidated limited liability company	0	0	(455)	0
Loss from investment in unconsolidated limited liability company	0	(33)	(122)	(188)
Comprehensive and net loss	(4,976)	(5,858)	(16,661)	(15,699)
Series B convertible preferred stock dividends	(1,347)	(1,190)	(3,918)	(3,463)
Net loss attributable to common stockholders	$ (6,323)	$ (7,048)	$ (20,579)	$ (19,162)
Net loss per share of common stock:
Basic and diluted (in dollars per share)	$ (0.59)	$ (0.67)	$ (1.93)	$ (1.93)
Weighted average shares used in computing net loss per share of common stock:
Basic and diluted (in shares)	10,665,410	10,591,834	10,642,263	9,916,834

VIVE Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 5,907,000	$ 19,162,000
Accounts receivable, net of allowance for doubtful accounts of $15 and $66 as of September 30, 2022 and December 31, 2021, respectively	860,000	549,000
Inventory	1,615,000	1,472,000
Prepaid expenses and other current assets	1,222,000	1,055,000
Total current assets	9,604,000	22,238,000
Property and equipment, net	1,009,000	1,554,000
Investment in unconsolidated limited liability company	0	577,000
Other assets	1,541,000	1,544,000
Total assets	12,154,000	25,913,000
Current liabilities:
Accounts payable	1,108,000	1,480,000
Accrued liabilities	4,101,000	3,053,000
Note payable, current portion	5,628,000	0
Total current liabilities	10,837,000	4,533,000
Note payable, noncurrent portion	0	5,124,000
Other noncurrent liabilities	133,000	1,190,000
Total liabilities	10,970,000	10,847,000
Commitments and contingences (Note 9)
Stockholders’ equity:
Common stock, $0.0001 par value; 75,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 10,698,857 and 10,619,846 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	1,000	1,000
Additional paid-in capital	259,697,000	256,918,000
Accumulated deficit	(258,514,000)	(241,853,000)
Total stockholders’ equity	1,184,000	15,066,000
Total liabilities and stockholders’ equity	12,154,000	25,913,000
Series B Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock	0	0
Series C Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock	$ 0	$ 0

About Viveve Medical Inc

Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

CEO	Ms. Deborah Ann Jorn M.B.A.
WEBSITE	viveve.com
INDUSTRY	Medical Supplies
EMPLOYEES	47

Viveve Medical Inc Frequently Asked Questions

What is the ticker symbol for Viveve Medical Inc? What does VIVE stand for in stocks?

VIVE is the stock ticker symbol of Viveve Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viveve Medical Inc (VIVE)?

As of Fri May 17 2024, market cap of Viveve Medical Inc is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIVE stock?

You can check VIVE's fair value in chart for subscribers.

What is the fair value of VIVE stock?

You can check VIVE's fair value in chart for subscribers. The fair value of Viveve Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Viveve Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VIVE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Viveve Medical Inc a good stock to buy?

The fair value guage provides a quick view whether VIVE is over valued or under valued. Whether Viveve Medical Inc is cheap or expensive depends on the assumptions which impact Viveve Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIVE.

What is Viveve Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VIVE's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIVE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Viveve Medical Inc's stock?

In the past 10 years, Viveve Medical Inc has provided -1 (multiply by 100 for percentage) rate of return.